No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Some Shareholders Feeling Restless Over Shandong Wohua Pharmaceutical Co., Ltd.'s (SZSE:002107) P/S Ratio
Wohua Pharmaceuticals: Report for the third quarter of 2024
Shandong Wohua Pharmaceutical: Half-year report for the year 2024.
Shandong Wohua Pharmaceutical: Summary of Half-Year Report in 2024.
Shandong Wohua Pharmaceutical: 2024 Interim Performance Forecast
Shandong Wohua Pharmaceutical Co., Ltd.'s (SZSE:002107) Share Price Could Signal Some Risk
